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a b s t r a c t
Objective: Gamma-globulin treatment reduces experimental atherosclerosis by modulating immune
function; however the effect of IgM on atherosclerosis is not known.We investigated the effect of serum-
derived, non-immune polyclonal IgM (Poly-IgM) on atherosclerosis in mice with advanced disease and
also assessed its immune-modulatory effects.
Methods and results: Aortic atherosclerosis was assessed in apoE−/− mice fed atherogenic diet starting
at 6 weeks of age. In addition, mice were also subjected to perivascular cuff injury to the carotid artery
at 25 weeks of age to induce accelerated atherosclerosis. At the time of injury, the mice were treated
weekly with a commercially available Poly-IgM (0.4mg/mouse) or PBS for 4 weeks and euthanized at
29 weeks of age. Poly-IgM reduced aortic atherosclerosis, and reduced lesion size in the aortic sinus and
injured carotid artery, without signiﬁcant changes in serum cholesterol levels. Poly-IgM treatment was
associated with increased anti-oxLDL IgG titers and a reduction in the % splenic CD4+ T cells compared
+to controls. The splenic CD4 T cell cultured from the Poly-IgM treated mice had reduced proliferation
in vitro compared with controls.
Conclusion: Poly-IgM treatment reduced aortic and accelerated carotid atherosclerosis in apoE−/− mice
in association with increased anti-oxLDL IgG titers, and reduced number and proliferative function of
splenic CD4+ T cells. Our study identiﬁes a novel athero-protective and immunomodulatory role for
non-immune polyclonal IgM.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.. Introduction
Atherosclerosis is a complex disease characterized by an inﬂam-
atory response that is modulated by the immune system [1,2].
vidence supporting the role of the immune response to the
isease has accumulated such that modulation of the immune
esponse is now viewed as a potential avenue of therapy [3].
ntravenous immunoglobulin (ivIg) is used to modulate immune
unction in various auto-immune diseases. Its potential thera-
eutic use in atherosclerosis has been demonstrated in animal
odels of both spontaneous atherosclerotic disease and accel-
rated lesion formation [4,5]. The mechanism of action involves
own-modulation of unfavorable immune function, including
eduction of inﬂammatory cytokines [5]. Other known effects of
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oi:10.1016/j.atherosclerosis.2011.10.002ivIg treatment include enhancement of the auto-antibody reper-
toire and down-regulation of T cell function [4]. Recent reports
have suggested that the immune-regulatory role of immunoglobu-
lin treatment may not be limited to the IgG fraction. IgM may have
similar properties that result in down-regulation of the inﬂam-
matory response [6–8]. Furthermore, we recently reported that
non-immune, serum-derived polyclonal IgM antibodies were just
as effective as IgG antibodies in reducing neointimal formation
after arterial injury. The results we reported were independent
of their modulatory effect on the immune system since the
study was conducted using immune-deﬁcient Rag-1−/− mice [9].
We sought to extend the ﬁndings by using serum-derived poly-
clonal IgM in hypercholesterolemic apoE−/− mice. The effect of
serum-derived polyclonal IgM on both spontaneous atheroscle-
rosis and accelerated lesion formation were tested and potential
immune-regulatory properties were investigated. Our results pro-
vide evidence that polyclonal IgM reduces atherosclerosis and
modulates immune function by enhancing the auto-antibody
repertoire and down-regulating number and proliferation of CD4+
T cells.
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Table 1
Effect of polyclonal IgM treatment on atherosclerosis.
% plaque area (en face) Aortic sinus lesion area (mm2) Carotid artery lesion area (mm2)
PBS 21.01 ± 5.05 (n=15) 0.64 ± 0.11 (n=8) 0.034 ± 0.025 (n=12)
















































* p<0.05 vs. PBS.




rom Jackson Laboratories (Bar Harbor, ME) at 6 weeks of age and
ere fed Western type diet (0.2% cholesterol, 20% fat, TD88137,
arlan Teklad) throughout the duration of the experiment. At the
ge of 25 weeks, a non-occlusive plastic cuff (length=2.5mm,
nternal diameter =0.51mm; Cole-Parmer Instrument Co.) was
septically placed around the right carotid artery and the skin
ncision was closed as previously described [10]. The mice then
eceived intra-peritoneal injections of serum-derived mouse poly-
lonal IgM (Poly-IgM, Rockland) at a dose of 0.4mg/mouse, or PBS
nce aweekuntil euthanasia fourweeks later. Ahybridomacell line
ecreting a monoclonal anti-phosphorylcholine IgM with the T15
diotype (HPCM2 cells, a generous gift from Dr. Patricia Gearhart
t NIH/NIA) was maintained [11] as a source for injection of anti-
hosphorylcholine IgM to another group of mice also at a dose of
.4mg/mouse until euthanasia four weeks later. The dosewas cho-
en based on a previous report that after injection of 0.4mg IgM the
ean level of IgM in Rag1−/− mouse was similar to that of normal
ouse [12].
At euthanasia, blood was collected and the aorta and carotid
rteries were perfused with 0.9% saline for 10min. Harvested
arotid arteries were embedded in OCT compound (Tissue-Tek,
llegiance), and frozen at −80 ◦C. The collected spleenswere either
ash-frozen or processed for ﬂow cytometric analysis and cell
ulture. Aortas were collected for en face atherosclerotic lesion
taining with Oil-Red-O [13]. All procedures were approved by the
nstitutional Animal Care and Use Committee.
.2. Morphometric measurement and immunohistochemistry
Frozen sections (6–8m thick) were collected from the
njured right carotid arteries and contra-lateral uninjured left
arotid arteries. Four sections were collected on each slide and
0–25 slides were collected from each injured arterial seg-
ent, as described previously [14]. Slides were stained with
ematoxylin and eosin, and the vessel area measured using
omputer assisted morphometric analysis (Image-Pro Plus). The
easurements of sections from each animal were averaged for
nalysis.
For monocyte/macrophage staining, sections were ﬁxed in
ce-cold acetone for 5min and standard immunohistochemical
rotocol was performed using monocyte/macrophage antibody
MOMA-2, Serotec). Omission of primary antibody was used as
egative control.
For Oil Red O staining, frozen sections were ﬁxed in 4%
araformaldehyde at room temperature for 30min. Slides were
tained with 0.24% Oil Red O in 60% isopropanol for 20min
nd counterstained with hematoxylin and fast-green. The stain
rea was measured using computer assisted morphometric
nalysis.
En face preparations of the aortas were also visualized and ana-
yzed using computer assisted morphometric analysis.2.3. ELISA
Antibody titer to oxLDL was assessed using standard ELISA
technique. Brieﬂy, plates were coated with 10g/ml Cu-oxLDL
(Biomedical Technologies) as capture antigen. Sera were diluted
(1:100 for IgG or 1:50 for IgM titers) and incubated on coated plates
for 2h in 4 ◦C, washed and detected using HRP labeled anti mouse
IgG (Pierce) or anti mouse IgM with the ABTS system (SBA). Values
are expressed as OD 405. Total serum IgM levels were measured
using a commercially available kit (Biosource).
2.4. Serum cholesterol
Serum cholesterol levels were measured using commercially
available kits (Sigma; Wako).
2.5. Flow cytometry
After RBC lysis, splenocytes were stained with ﬂuorescent
labeled antibodies for CD4, CD8b, and CD28 (eBiotech) and sub-
jected to ﬂow cytometric analysis (BD Bioscience). Binding of
polyclonal IgM to T cells was tested using FITC-labeled Poly-IgM
and PE-labeled CD4 or CD8b antibodies. FITC-labeled poly IgM was
produced in the laboratory using labeling kit from Pierce.
2.6. Splenocyte proliferation
Splenocyteswere labeledwith CFSE (2.5mM,Molecular Probes)
for 10min in 37 ◦C, washed, and cultured in RPMI media with 10%
FBS. Cells were then treated with Concanavalin-A (Con-A, 3g/ml)
and collected 5 days later. Cells were stained with PE-labeled CD4
or CD8b antibody for ﬂow cytometric analysis. CFSE staining inten-
sity was analyzed using lymphocytes gated on either CD4 or CD8b.
Analysiswas performedbydetermining the percentage of cells that
had reduced CFSE intensity, indicating cell proliferation.
2.7. Statistical analysis
Results are presented asmean± SD. Student’s t-test was used to
test for signiﬁcance, set at p<0.05.
3. Results
3.1. Polyclonal IgM reduces atherosclerosis
Serum IgM levels were measurably increased in the Poly-
IgM treated mice compared with PBS treated mice at euthanasia
and were comparable between the two groups (128±4 vs.
119±3g/ml, respectively;p=0.08). TreatmentwithPoly-IgMsig-
niﬁcantly reduced en-face aortic atherosclerosis compared with
PBS treatment (Fig. 1A and B; Table 1). Plaque area in the aor-
tic sinus was signiﬁcantly reduced by Poly-IgM treatment (Fig. 1C
and D; Table 1). Accelerated lesion formation induced by cufﬁng
of the right carotid artery was also reduced by Poly-IgM treatment
(Fig. 1E and F; Table 1). No lesionswerepresent in the contra-lateral
left carotid arteries (Fig. 1G and H). No signiﬁcant changes were
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Fig. 1. Representative photograph of en face staining of atherosclerotic plaques in the aorta of PBS treated control (A) and polyclonal IgM treated (B) mice. Oil Red O stain
of aortic sinus plaques from PBS treated (C) and polyclonal IgM treated mice (D). Bar =100m. Hematoxylin and eosin stain of 28-day injured right carotid artery from
PBS treated (E) and polyclonal IgM treated (F) mice. Bar =50m. Contra-lateral uninjured left carotid artery from PBS treated (G) and polyclonal IgM treated (H) mice.
Bar =100m.
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Table 2
Serum cholesterol proﬁle.
Total cholesterol LDL HDL Triglyceride
















































+Poly-IgM 999 ± 563 367 ± 131 31 ± 21 48 ± 43
ll values are in mg/dl.
bserved in macrophage or lipid content (not shown) in the aortic
inus and right carotid artery lesion, and serum cholesterol levels
ere comparable between the two groups (Table 2).
.2. Alteration of the natural antibody repertoire by polyclonal
gM
The immunemodulatory effect of intravenous immunoglobulin
reatment is attributed to several mechanisms, including enhance-
ent of the natural antibody repertoire and down-regulation of
cell function. The ﬁrst mechanism was tested by determining
elative anti-oxLDL antibody titers in the experimental groups.
xLDL IgG was signiﬁcantly increased in the Poly-IgM group com-
ared with PBS group (Fig. 2A). There was a signiﬁcant correlation
etween anti-oxLDL IgG and en-face aortic atherosclerosis in the
oly-IgM treated group (p=0.05; Fig. 2B) but not in the PBS treated
roup (p=0.4).
There was no signiﬁcant difference in anti-oxLDL IgM titers
etween the two groups (Fig. 2C). However, as in the case of
nti-oxLDL IgG titers, there was a signiﬁcant correlation between
nti-oxLDL IgM titers and en-face aortic atherosclerosis in the Poly-
gM treated group (p=0.015; Fig. 2D) but not in the PBS treated
roup (p=0.7).
.3. Down-regulation of T cells by Poly-IgM treatment
To determine the T cell population to which Poly-IgM binds,
ow cytometry was performed on spleen cells from non-treated
poE−/− mice using PE-labeled CD4 or CD8b antibodies and FITC-
abeled Poly-IgM or PBS. The results showed that Poly-IgM has the
bility to bind to both CD4+ T cells and CD8+ T cells (Fig. 3A and B).
Flow cytometry of CD4+ T cells from spleens of Poly-IgM treated
ice showed a signiﬁcant reduction in their number compared
ith mice treated with PBS (Fig. 4A). This was not observed in
D8b+ T cells (Fig. 4B). CD4+CD28+ T cells were also signiﬁcantly
educed in Poly-IgM treated mice compared with mice treated
ith PBS (Fig. 4C). There was no difference in CD8b+CD28+ T
ells between the two groups (Fig. 4D). To further determine if
D4+ T cells from Poly-IgM treated mice had reduced response
o an immunogenic challenge, splenocytes from Poly-IgM and PBS
reated mice were cultured after staining with CFSE and treated
ith Con-A to determine proliferative activity (Fig. 4E, inset). CD4+
plenocytes from Poly-IgM treated mice proliferated signiﬁcantly
ess thanCD4+ splenocytes fromPBS treatedmice (Fig. 4E). Prolifer-
tion of CD8b+ splenocytes was not signiﬁcantly different between
he two groups (Fig. 4F).
.4. Atherosclerosis is not reduced by a mouse monoclonal IgM
ntibody
To determine if the effect of Poly-IgM was speciﬁc for poly-
eactive natural antibodies, we treated another group of mice with
he mouse monoclonal anti-phosphorylcholine IgM antibody (PC-
gM) which we previously demonstrated to reduce syngeneic vein
raft atherosclerosis [11]. Treatment with PC-IgM did not reduce
therosclerosis in the aorta (17.25±7.00%; n=12) or in the cuffed
arotid artery (0.057±0.049mm2; n=6). Anti-oxLDL IgG titersrosis 220 (2012) 59–65
were also unchanged by PC-IgM treatment (not shown), indicating
that there was no effect on the natural antibody repertoire.
4. Discussion
The results of our study show reduced spontaneous atheroscle-
rosis in the aorta and decreased accelerated lesion formation in
the cuffed carotid artery by polyclonal IgM treatment in hyper-
cholesterolemic apoE−/− mice. It should be noted that these
favorable results were observed despite a relatively short dura-
tion of treatment (4 weeks) which was initiated at 25 weeks
of age when mice were expected to already have advanced
atherosclerotic lesions. This is noteworthy since many experimen-
tal therapies have been tested prior to, or at the earlier stages
in the evolution of atherosclerotic disease [4,5,13,14]. Indeed,
we have previously shown that timing affects the efﬁcacy of
immunization for atherosclerosis [13]. The current study shows
that polyclonal IgM was effective in reducing advanced sponta-
neous aortic atherosclerosis as well as injury accelerated carotid
atherosclerosis.
The serumIgMlevels in thePoly-IgMtreatedmicewereelevated
but did not reach statistical signiﬁcance most likely because the
serumsamplewere takenat euthanasia,which is oneweekafter the
last Poly-IgM injection. We have previously reported the kinetics
of absorption of injected IgM in mice [11].
Immunoglobulin therapy is known to have multiple effects on
immune function, including enhancing the auto-antibody reper-
toire and down-modulating T cell function. We ﬁrst tested the
auto-antibody repertoire to oxLDL. IgG and IgM antibodies to
oxLDL are known to occur spontaneously, and we have previously
shown that the titers increase with age [15]. Our results show
that polyclonal IgM treatment resulted in increased anti-oxLDL
IgG antibodies. Anti-oxLDL IgG antibody titers were inversely cor-
related with en-face aortic atherosclerosis in the polyclonal IgM
treated group, but not in the PBS group. In addition, although
there was no difference in anti-oxLDL IgM titers between the two
groups, an inverse correlation between anti-oxLDL IgM titers and
en-face aortic atherosclerosis, was observed in the polyclonal IgM
treated group but not in the PBS group. The results show that
the anti-oxLDL antibody repertoire was modiﬁed by polyclonal
IgM treatment in association with reduced atherosclerotic plaque
area. This is in contrast to the report by Nicoletti et al. wherein
treatment of apoE−/− mice with intravenous IgG did not affect
anti-oxLDL IgG titers, but did reduce anti-oxLDL IgM titers [4].
Thus, it appears that the effects of intravenous IgG on the auto-
antibody repertoire are different from those of polyclonal IgM
observed in our study. Interestingly, LDLR−/− mice deﬁcient in
soluble IgM had signiﬁcantly reduced anti-oxLDL IgG titers asso-
ciated with increased atherosclerosis [16]. Thus, IgM may have yet
undeﬁned functions that modulate the auto-antibody repertoire in
atherosclerosis.
Nicoletti et al. also showed that the proliferative capacity of T
cells collected from the lymph nodes was inhibited by intravenous
IgG treatment [4]. However, the subtype of T cells affected was
not identiﬁed in that study. We show that CD4+ T cells are pref-
erentially reduced in the spleen of polyclonal IgM treated mice,
with no signiﬁcant effect on CD8b+ T cells. The pathogenic role of
CD4+ T cells in atherosclerosis is well described [17] and the spe-
ciﬁc reduction likely contributed to the effect on plaque growth.
We further tested the proliferative capacity of both cell types after
stimulation with Con-A. CD4+ T cells from polyclonal IgM treated
mice showed signiﬁcantly reduced proliferation than CD4 T cells
from PBS treatedmice. Consistent with the in vivo result, prolifera-
tion of CD8+ T cells was not signiﬁcantly affected by polyclonal IgM
treatment.














pig. 2. Increased oxLDL IgG antibody titers in polyclonal IgM treated mice compare
etween anti-oxLDL IgG titers and en-face aortic atherosclerosis in the polyclonal Ig
reatment (C), but were negatively correlated with en-face aortic atherosclerosis (D
IgM-enriched intravenous Ig has been shown to decrease
xpressionof theTcell activationmarkerCD69 inahumanizedSCID
odel [8]. In our study, CD4+CD28+ T cells from Poly-IgM treated
ice were signiﬁcantly reduced compared to PBS. Our results are
n agreement with their observation that IgM, like intravenous IgG
lso regulates T cell function. However, it remains unclear how
oly-IgM treatment regulates T cell function. IgM puriﬁed from
erumcontains anti-leukocyte antibodies (IgM-ALA) that immuno-
recipitated lymphocyte markers such as CD3 and CD4, and have
een shown to inhibit T cell function [18]. Our results showing
ig. 3. FITC-labeled polyclonal IgM (Poly-IgM) was used to stain PE-labeled CD4 (A) or CD
olyclonal IgM or PBS.y-IgM) with PBS treated control mice (A). *p<0.05. Negative correlation was found
ated mice (B). Anti-oxLDL IgM antibody titers were not affected by polyclonal IgM
binding of FITC labeled Poly-IgM to a small percentage of T cells
and alteration of CD4+ T cell function is consistent with their
report.
We recently reported that natural antibodies of the IgG and IgM
isotypes reduced neointimal formation in the immune-deﬁcient
Rag-1−/− mice [9]. The current report is in agreement with our
previous work on the inhibitory effect of IgM on vascular lesion
formation. However, because the Rag-1−/− mice have no mature
immune cells, the effects were likely mediated through a different
mechanism.
8 (B) cells to assess Poly-IgM binding to T cells. Control for staining was unlabeled
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Fig. 4. Percentage of CD4+ cells from the spleen of mice treated with polyclonal IgM were signiﬁcantly reduced compared with PBS treated control mice (A). No signiﬁcant
effect was observed in CD8b+ cells (B). Polyclonal IgM treatment signiﬁcantly reduced the percentage of CD4+CD28+ T cells in the spleen compared to PBS treated group
















DC). No signiﬁcant difference was observed in the CD8b CD28 T cells in the splee
oncanavalin A, was reduced by polyclonal IgM treatment (E). Inset (E) shows CFSE
igniﬁcant difference was observed in CD8b+ splenocytes (F). *p<0.05; n=4 each.
In conclusion, our study shows that polyclonal IgM reduces
dvanced spontaneous aortic atherosclerosis as well as injury-
nduced accelerated carotid atherosclerosis in apoE−/− mice.
olyclonal IgM treatment signiﬁcantly enhanced the auto-antibody
epertoire to oxLDL and preferentially reduced the number and
roliferative function of splenic CD4+ T cells without signiﬁ-
antly affecting CD8+ T cells. Polyclonal IgM may be an alternative
herapeutic approach to modulate the immune response to
therosclerotic disease.
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